# Ipamorelin Dosage in Research: Doses, Routes, and Half-Life Studied > Ipamorelin dosage as studied in research — the doses, routes, and ~2-hour half-life measured in animals and the one human study. Research context only, no prescription. The doses, routes, and pharmacokinetics that studies actually used — reported in the third person, as research context, never as a human protocol. ## Read this first This page describes ipamorelin dosage the way the studies report it — which species got how much, by which route, for how long — and nothing more. It is not a protocol, a recommendation, or a how-to. There is no established human dose for ipamorelin, because it was never approved and its single human efficacy trial used a hospital-administered intravenous regimen that did not work [3]. Where community combination protocols come up, they are flagged as anecdotal and unvalidated, with no peer-reviewed human dosing basis. The useful, real numbers here are the pharmacokinetics — how long ipamorelin lasts and how fast the GH pulse peaks — because those were measured in people [2]. Everything framed as "take this much" anywhere online is extrapolation, not evidence. ## Doses and routes used in studies Across the published record, ipamorelin has been administered in tightly controlled experimental settings: - **Human pharmacokinetics:** single intravenous infusions of 4.21 to 140.45 nmol/kg over 15 minutes in healthy male volunteers [2]. - **Human Phase 2 trial:** 0.03 mg/kg intravenously twice daily for up to 7 days in bowel-resection patients [3]. - **Rat bone growth:** 18, 90, and 450 µg/day subcutaneously, divided three times daily, for 15 days [4]. - **Ferret cachexia (2024):** 1–3 mg/kg intraperitoneally [5]. The routes studied span intravenous (human trials and rodent efficacy), subcutaneous (the rodent bone and body-composition work, and the dominant route in community use), intraperitoneal (rodent and ferret studies), and intranasal (rodent pharmacokinetics, around 20% bioavailability). Ipamorelin itself is not orally active — only engineered analogs achieve oral absorption [7]. Note the gap: the route most people actually use, subcutaneous self-injection, has no published human dosing or safety characterization at all. ## Half-life and how fast the GH pulse arrives This is the part of ipamorelin dosage that rests on real human data. In healthy volunteers, ipamorelin showed a terminal half-life of approximately **2 hours**, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The pharmacokinetics were linear and dose-proportional. The growth-hormone response it triggers is a single discrete pulse that peaks about 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance runs roughly five-fold lower than the older peptide GHRP-6. The short half-life and quick, single GH pulse are why the compound is studied as a pulsatile stimulus rather than a steady one. ## How much cjc-1295 ipamorelin should i take There is no evidence-based answer to how much cjc-1295 ipamorelin someone should take, and this site will not invent one. No controlled human trial has tested the CJC-1295 + ipamorelin combination for any outcome, so there is no validated dose, ratio, or schedule for it. The community subcutaneous protocols circulating online are not supported by peer-reviewed human dosing data and are described here only as anecdotal practice, not as guidance. The single controlled human ipamorelin regimen on record (0.03 mg/kg IV twice daily) was a hospital-administered trial dose that failed its endpoint [3] — not a template for self-use. Any specific milligram figure attached to a "stack" is extrapolation from animal pharmacology, not a finding. ## How to reconstitute cjc-1295 ipamorelin 5mg On the question of how to reconstitute cjc-1295 ipamorelin 5mg, the only thing the research-supply literature actually documents is general peptide-handling: ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. These are general handling observations from the supply literature, **not** a clinical preparation instruction and not a step-by-step protocol for human use. No validated human reconstitution or dosing procedure exists for ipamorelin, alone or combined with CJC-1295. ## Stability and handling notes Ipamorelin's physical handling is straightforward in research terms and unremarkable for a peptide. It ships lyophilized and is reconstituted before use; the solution is heat- and freeze-thaw-sensitive and kept cold. A separate, non-handling caution belongs here too: research-grade ipamorelin from unregulated suppliers is not subject to pharmaceutical quality control, so identity, purity, and sterility are unverified [3]. The handling literature tells you how the powder behaves; it tells you nothing about whether a given gray-market vial contains what its label claims. --- A forward-looking, fully cited read of the ipamorelin research record and its regulatory status — a reading console, not a clinic, not a vendor, not a prescription, and not legal advice.